After 28 days, 22.5% of patients on Spravato attained remission versus 7.6% of patients in placebo. With MDD, remission is defined by a specified MADRS score. Because of the risk of dangerous ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

“Spravato is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days, without the need for daily oral ...

"Spravato is now available as a stand-alone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days -- without the need for daily oral ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

total score within 24 hours after the initial dose, with effects sustained for at least four weeks. Spravato’s safety profile aligns with existing data for oral antidepressants, with no new ...

According to the company, approval was supported by a pivotal placebo-controlled study in which Spravato demonstrated rapid and superior improvements in depressive symptoms as early as 24 hours, which ...

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, multicenter, placebo-controlled trial. On day 28 of the trial, patients taking ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, multicenter, placebo-controlled trial. On day 28 of the trial, patients taking ...

Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for J&J but only as an adjunct therapy to oral antidepressants for TRD.

The study showed that patients treated with SPRAVATO® alone experienced relief from depressive symptoms as early as 24 hours after administration, with continued improvement at 28 days.